Welcome to our dedicated page for Dalrada Financl news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financl stock.
Dalrada Financial Corporation (DFCO), now identified in company communications as Dalrada Technology Group, Inc., generates news across clean energy, semiconductor deposition technology, precision manufacturing, and health care. Its press releases highlight developments within core segments such as Dalrada Climate Technology, Deposition Technology (Deptec), and Genefic Specialty Pharmacy.
News related to clean energy and climate technology often covers contracts, distribution agreements, and facility developments involving Dalrada’s heat pump technology. Examples include agreements for heat pump installations in European light industrial facilities and a master distribution agreement in the United States that targets sales of commercial and residential heat pump units across multiple regions.
Updates from Deposition Technology (Deptec) focus on advanced thin-film deposition and semiconductor-related tools. Company announcements have detailed the availability of the proprietary Spectroptix plasma spectrometer for advance ordering, as well as the establishment of a manufacturing and R&D facility in Portland, Oregon, to support deposition technology production and sales in North America and beyond.
In the health care segment, news frequently centers on Genefic, Inc. and Genefic Specialty Pharmacy. Communications include interviews and updates that describe revenue growth, expansion of specialty pharmacy services, and the operation of licensed diagnostic laboratories and an infusion pharmacy.
Dalrada’s news flow also includes corporate and governance updates, such as changes to its board of directors, executive appointments, and the selection of independent registered public accounting firms. Together, these items provide insight into the company’s strategic direction, operational focus, and corporate evolution from Dalrada Financial Corporation (DFCO) to Dalrada Technology Group, Inc. (DHTI).
Dalrada Financial Corporation (OTCQB: DFCO) has appointed Brian Murphy to its Clean Energy Advisory Board. Murphy, a global business executive with extensive experience in technology and market development, will contribute significantly to the company's clean energy initiatives. His background includes roles at major firms like Cisco, Vodafone Americas, and Accenture Digital, focusing on driving profitable growth and developing innovative market strategies.
Chairman and CEO Brian Bonar expressed enthusiasm for Murphy's appointment, highlighting his capability to translate market needs into solutions. Murphy aims to enhance Dalrada's position in the clean energy sector, targeting energy cost and carbon output reduction while fostering company growth.
Dalrada Financial Corporation (OTCQB: DFCO) announced that its healthcare division, Watson Rx Solutions, has received Healthcare Merchant Accreditation from the National Association of Boards of Pharmacy (NABP). This accreditation validates Watson Rx as a licensed pharmaceutical retailer, adhering to legal standards and best practices. As a result, Watson Rx is now eligible for a “.pharmacy” domain, aligning it with major retailers like CVS and Walgreens.
Watson Rx's focus on improving accessibility and patient care is reinforced by this honor. Adam Myers, Head Pharmacist, emphasized the commitment to personalized health solutions, showcasing a dedication to enhancing patient outcomes.
Dalrada Financial Corporation (OTCQB: DFCO) announced its healthcare division, Genefic, will establish a new corporate headquarters in Rancho Bernardo, San Diego. The two-story, 8,500 square-foot facility will enhance Genefic's capacity to advance its healthcare product and technology development. It will provide office space, laboratory, pharmacy services, and support for nursing education classes. Expected to be operational later this month, the new headquarters aims to strengthen Genefic’s presence in Southern California and improve health outcomes through innovative patient care solutions.
Dalrada Corporation (DFCO) reported a 23% quarterly revenue increase, totaling $5.3 million for Q2 2023, ending December 31, 2022. CEO Brian Bonar noted significant growth stemming from investments in intellectual property, resulting in a $400,000 asset boost. The company has a backlog of $52 million, signaling strong future revenue potential. Key segments included Precision Manufacturing at $1.1 million and Health at $2 million. Additionally, Dalrada acquired Bothof Brothers Construction, enhancing its service offerings. The financial outlook appears positive as operational growth continues across various sectors.
Dalrada Financial Corporation (OTCQB: DFCO) has announced a new 10-year lease for a 20,000-square foot facility in Livingston, Scotland. This location will serve as the UK headquarters for Dalrada Technology Ltd., housing its subsidiaries Deposition Technology (DepTec) and Likido. The new site aims to enhance production capabilities for clean energy solutions and semiconductor technologies, catering to increasing global demand. CEO Brian Bonar emphasized the facility's significance in fostering innovation and cost efficiency. The move is expected to be completed by March 1.
Dalrada Financial Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as chair and Pauline Gourdie as vice chair of its new health care division, Genefic. Hershkowitz has been a board member since July 2020, and Gourdie joined in August 2019. The board also includes four other members with extensive industry experience. Hershkowitz expressed excitement about leveraging technology for global health improvements. The management change is seen as a step towards enhancing leadership in health care innovations.
Dalrada Financial Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as the Chairman and CEO of its new health division, Genefic, previously known as Dalrada Health. With nearly 40 years of experience in healthcare and business, Hershkowitz aims to enhance patient care through innovative technologies and products. His leadership is expected to drive growth and align with Dalrada's global vision. Brian Bonar, the founder, highlighted Hershkowitz's strategic insight and understanding of the industry as essential for Genefic's future success.
Summary not available.
Dalrada Corporation (OTCQB: DFCO) has appointed MGO (Macias Gini and O’Connell LLP) as its new independent auditor starting from the quarter ending December 31, 2022. This decision is part of Dalrada's business transformation, aimed at aligning with its growing segments, especially in clean energy and precision manufacturing. The company has also reported strong triple-digit growth in the 2022 fiscal year, highlighting significant market demand and federal incentives for its new Dalrada Energy Services. The partnership with MGO is expected to support the company's ongoing expansion.
Dalrada Financial Corporation (OTCQB: DFCO) announces that its subsidiary, Empower Genomics, has received approval from the CDC to distribute and administer COVID-19 vaccines. This positions Empower Genomics alongside major pharmacies in serving at-risk populations in the San Diego area. The program includes Flu and COVID-19 vaccinations for various age groups. California has also granted funding to support these efforts, particularly for vaccinating infants and toddlers. Empower Genomics continues providing onsite COVID-19 testing and encourages online appointment bookings through the CDPH.